<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03137173</url>
  </required_header>
  <id_info>
    <org_study_id>BPR-CS-008</org_study_id>
    <nct_id>NCT03137173</nct_id>
  </id_info>
  <brief_title>Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections</brief_title>
  <official_title>A Randomized, Double-blind, Multicenter Study to Establish the Safety and Efficacy of Ceftobiprole Medocaril Compared With Vancomycin Plus Aztreonam in the Treatment of Acute Bacterial Skin and Skin Structure Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Basilea Pharmaceutica</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department of Health and Human Services</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Basilea Pharmaceutica</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and efficacy of ceftobiprole medocaril
      versus vancomycin plus aztreonam in the treatment of patients with acute bacterial skin and
      skin structure infections.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 20, 2018</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective early clinical response</measure>
    <time_frame>48 - 72 h after start of study drug treatment</time_frame>
    <description>Comparison of early clinical response, including ≥ 20% reduction from baseline in the primary lesion area (based on ruler measurements), in the intent-to-treat (ITT) population</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigator-assessed clinical success</measure>
    <time_frame>15 - 22 days after randomization</time_frame>
    <description>Comparison of investigator-assessed clinical success (based on resolution of baseline signs and symptoms of the primary infection) in the ITT and clinically evaluable populations</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">674</enrollment>
  <condition>Acute Bacterial Skin and Skin Structure Infections</condition>
  <arm_group>
    <arm_group_label>Ceftobiprole medocaril</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ceftobiprole medocaril 500 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vancomycin plus Aztreonam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vancomycin 1000 mg (or 15 mg/kg); Aztreonam 1000 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftobiprole medocaril</intervention_name>
    <description>Ceftobiporole medocaril as 2 h infusion</description>
    <arm_group_label>Ceftobiprole medocaril</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin plus Aztreonam</intervention_name>
    <description>Vancomycin as 2 h infusion; Aztreonam as 0.5 h infusion</description>
    <arm_group_label>Vancomycin plus Aztreonam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female ≥18 years of age

          -  Diagnosis of acute bacterial skin and skin structure infection (ABSSSI), with a
             regional or systemic sign of infection

          -  Requirement for intravenous bacterial treatment

        Exclusion Criteria:

          -  Use of any systemic antibacterial treatment within 14 days

          -  Contraindication to the administration of the study treatments, including known
             clinically-relevant hypersensitivity

          -  Uncomplicated skin and skin structure infection

          -  Primary ABSSSI due to or associated with any of the following: diabetic foot
             infection, gangrene, or perianal abscess; concomitant infection at another site;
             infected burns; decubitus, chronic, or ischemic ulcer; evolving necrotizing process;
             infections at vascular catheter sites or involving thrombophlebitis

          -  Requirement for more than two surgical interventions in the operating room

          -  Severe sepsis or septic shock
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kamal Hamed, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Basilea Pharmaceutica</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kamal Hamed, MD, MPH</last_name>
    <phone>+41 61 567 15 88</phone>
    <email>kamal.hamed@basilea.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marc Engelhardt, MD</last_name>
    <phone>+ 41 61 567 15 46</phone>
    <email>marc.engelhardt@basilea.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>eStudySite</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shandel Odom</last_name>
      <phone>619-567-1550</phone>
      <email>sodom@estudysite.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>eStudySite</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Selma Luedtke</last_name>
      <phone>702-410-2970</phone>
      <email>sluedtke@estudysite.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2017</study_first_submitted>
  <study_first_submitted_qc>April 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 2, 2017</study_first_posted>
  <last_update_submitted>February 23, 2018</last_update_submitted>
  <last_update_submitted_qc>February 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Aztreonam</mesh_term>
    <mesh_term>Ceftobiprole</mesh_term>
    <mesh_term>Ceftobiprole medocaril</mesh_term>
    <mesh_term>Cephalosporins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

